Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Dash Acquisitions Inc.

by · The Cerbat Gem

Dash Acquisitions Inc. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 28.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,958 shares of the medical research company’s stock after purchasing an additional 5,483 shares during the period. Thermo Fisher Scientific comprises approximately 4.8% of Dash Acquisitions Inc.’s investment portfolio, making the stock its 9th biggest position. Dash Acquisitions Inc.’s holdings in Thermo Fisher Scientific were worth $12,044,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank Julius Baer & Co. Ltd Zurich grew its holdings in Thermo Fisher Scientific by 100,798.8% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 406,539,228 shares of the medical research company’s stock worth $212,111,842,000 after acquiring an additional 406,136,310 shares during the period. BlackRock Inc. grew its holdings in Thermo Fisher Scientific by 2.1% during the 1st quarter. BlackRock Inc. now owns 31,423,285 shares of the medical research company’s stock worth $18,111,439,000 after acquiring an additional 633,163 shares during the period. State Street Corp grew its holdings in Thermo Fisher Scientific by 0.3% during the 2nd quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock worth $8,414,693,000 after acquiring an additional 55,458 shares during the period. Morgan Stanley grew its stake in shares of Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after buying an additional 1,764,312 shares during the period. Finally, FMR LLC grew its stake in shares of Thermo Fisher Scientific by 1.7% in the 1st quarter. FMR LLC now owns 11,354,044 shares of the medical research company’s stock valued at $6,544,130,000 after buying an additional 194,602 shares during the period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $454.41, for a total transaction of $4,544,100.00. Following the completion of the transaction, the chief executive officer now directly owns 131,175 shares in the company, valued at approximately $59,607,231.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.2 %

Thermo Fisher Scientific stock opened at $520.59 on Thursday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $609.85. The firm has a market capitalization of $201.14 billion, a price-to-earnings ratio of 34.04, a P/E/G ratio of 3.21 and a beta of 0.83. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a 50 day simple moving average of $476.45 and a 200 day simple moving average of $509.81.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $5.69 earnings per share for the quarter, beating analysts’ consensus estimates of $5.61 by $0.08. Thermo Fisher Scientific had a net margin of 13.68% and a return on equity of 18.88%. The business had revenue of $10.57 billion during the quarter, compared to analyst estimates of $10.60 billion. During the same period in the previous year, the business earned $5.08 EPS. Thermo Fisher Scientific’s revenue was down 1.0% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Tuesday, November 14th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 2.2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 16th. Investors of record on Friday, December 15th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $1.40 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 9.17%.

Analysts Set New Price Targets

Several brokerages have recently commented on TMO. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research note on Thursday, September 28th. They issued an “outperform” rating and a $603.00 target price for the company. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. HSBC initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday. They issued a “buy” rating and a $610.00 price target on the stock. TheStreet cut shares of Thermo Fisher Scientific from a “b-” rating to a “c+” rating in a research report on Monday, November 6th. Finally, Wells Fargo & Company raised shares of Thermo Fisher Scientific from an “underweight” rating to an “equal weight” rating and set a $475.00 price target on the stock in a research report on Wednesday, October 25th. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $597.53.

Get Our Latest Stock Analysis on Thermo Fisher Scientific

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading